split-banner-image

POSNOC

Closed

ANZ 1501/RD-5103-001-13: POSNOC

BCT Study Chair:

Bruce Mann

The standard surgical treatment for breast cancer involves surgery such as mastectomy, or excision of a tumour from the breast and also the removal of one or two “sentinel” lymph nodes from the armpit. The nodes are examined to check if cancer cells are present. If breast cancer has spread to the lymph nodes women may undergo a second operation to remove all the lymph nodes in the armpit or receive radiotherapy treatment to the armpit. Recent trials suggest that if there is only a limited amount of cancer in 1 or 2 sentinel nodes then further treatment of nodes may be unnecessary. It is possible that the other treatments routinely used in breast cancer treatment are sufficient to treat any remaining traces of cancer in the remaining nodes. If the outcome is the same, it may be possible to safely avoid further surgery (or radiation to the armpit) in these patients. The aim of the POSNOC trial is to find out if further axillary treatment is of benefit in women with macrometastases found in one or two lymph nodes.

INTERNATIONAL

1692

INTERNATIONAL

Total number of trial

participants internationally

AUSTRALIA & NEW ZEALAND

208

AUSTRALIA & NEW ZEALAND

Total number of trial participants

in Australia and New Zealand

INSTITUTIONS

22

INSTITUTIONS

Total number of participating institutions

in Australia and New Zealand

POSNOC PUBLICATIONS

2022

Recruitment, clinical equipoise, patient acceptance and compliance in the UK-ANZ POSNOC trial.

Goyal A, Bruce C, Sadiq S, Lewis M, Montgomery A, Mann GB, Badger H, Monson K, Jenkins V, Fallowfield L, Reed M, Dodwell D, Fairbrother P, Homer T, Vale L, Butt R, Miles E, Dowey S, Matthews L, Jarrett H, Jackson J, Ali A. San Antonio Breast Cancer Symposium. 2022; Abstract# P5-01-07, Abstract

2018

POSNOC – Positive sentinel node: Adjuvant therapy alone versus adjuvant therapy plus clearance or axillary radiotherapy.

Goyal A, Mann B, Thompson AM. SABCS 2018; PD8-05, Poster

POSNOC: Positive Sentinel Node – Adjuvant therapy alone versus adjuvant therapy plus clearance or axillary radiotherapy.

Goyal A, Mann B, Thompson AM, POSNOC trial management group. Journal of Clinical Oncology. 2018; 36(15_suppl):TPS600, Poster

2016

Maximising recruitment and retention of patients into UK-ANZ POSNOC trial.

Goyal A, Coleman RE, Dodwell D, Fallowfield L, Jenkins VA, Mann B, Reed MW, POSNOC Trial Management Group. SABCS 2016. 2016; OT3-03-02, Poster

Current Surgical Trials for the Management of Regional Node Disease.

Mann B. Asia-Pacific Journal of Clinical Oncology. 2016; 12(Suppl. S5):Abstract #115 (oral presentation), Comment

2015

POSNOC: Positive sentinel node – Adjuvant therapy alone versus adjuvant therapy plus clearance or axillary radiotherapy: A randomised trial looking at axillary treatment in early breast cancer.

Goyal A. SABCS 2015 2015; OT2-02-05, Poster

LEARN MORE ABOUT CLINICAL TRIALS

OUR ACHIEVEMENTS

Our research has been saving lives and changing practice since 1978.

GENETIC TESTING

Who should have genetic testing and what does a ‘strong family history’ mean.

BRCA1 & BRCA2 GENE MUTATIONS

What is a BRCA gene mutation and what options are available to prevent breast cancer.